Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lyka Labs Limited ( (IN:LYKALABS) ) has shared an update.
Lyka Labs Limited has announced that the National Company Law Tribunal, Ahmedabad Bench, has approved the amalgamation of Lyka Exports Limited with Lyka Labs under sections 230 to 232 of the Companies Act, 2013. The scheme, with an appointed date of April 1, 2022, consolidates the group’s operations and is expected to streamline its corporate structure and regulatory compliance.
Following the tribunal’s approval on March 16, 2026, the company is proceeding to file the necessary e-form INC-28 and related documents with the Registrar of Companies within the prescribed 30-day period. This procedural step will move the merger towards formal effectiveness, potentially improving operational efficiency and clarity for shareholders and other stakeholders.
More about Lyka Labs Limited
Lyka Labs Limited operates in the pharmaceutical industry, focusing on the development, manufacture and marketing of pharmaceutical formulations. The company serves domestic and international markets through its range of therapeutic products and has related entities, including Lyka Exports Limited, aligned to its core pharma business.
Average Trading Volume: 2,393
Technical Sentiment Signal: Sell
Current Market Cap: 1.9B INR
See more insights into LYKALABS stock on TipRanks’ Stock Analysis page.